Clinical Trial Update: Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluating Rituximab-HyperCVAD alternating with Rituximab-Methotrexate-Cytarabine for newly diagnosed diffuse large B-cell lymphoma with MYC …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burkitt-like Lymphoma
• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• HyperCVAD regimen
• METHOTREXATE (METHOTREXATE)
• Rituximab (rituximab)

Snippet

Sponsor: The University of Texas Health Science Center at San Antonio | Conditions: Newly Diagnosed Diffuse Large B-Cell Lymphoma, Intermediate (Burkitt-Like) Lymphoma | Phase 2 | Status: WITHDRAWN